3,268 Shares in Lantheus Holdings, Inc. (NASDAQ:LNTH) Acquired by Focus Financial Network Inc.

Focus Financial Network Inc. acquired a new stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 3,268 shares of the medical equipment provider’s stock, valued at approximately $292,000.

Several other large investors have also modified their holdings of the stock. CWM LLC increased its position in shares of Lantheus by 63.0% in the third quarter. CWM LLC now owns 750 shares of the medical equipment provider’s stock worth $82,000 after acquiring an additional 290 shares in the last quarter. Exchange Traded Concepts LLC raised its stake in Lantheus by 57.1% during the 3rd quarter. Exchange Traded Concepts LLC now owns 1,266 shares of the medical equipment provider’s stock valued at $139,000 after purchasing an additional 460 shares during the period. Creative Planning lifted its holdings in shares of Lantheus by 5.4% in the third quarter. Creative Planning now owns 24,988 shares of the medical equipment provider’s stock valued at $2,742,000 after purchasing an additional 1,274 shares in the last quarter. Bleakley Financial Group LLC acquired a new stake in shares of Lantheus in the third quarter worth $231,000. Finally, AlphaMark Advisors LLC grew its holdings in shares of Lantheus by 556.5% during the third quarter. AlphaMark Advisors LLC now owns 3,578 shares of the medical equipment provider’s stock valued at $393,000 after buying an additional 3,033 shares in the last quarter. 99.06% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Lantheus news, Director James H. Thrall sold 1,000 shares of the business’s stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total value of $94,760.00. Following the completion of the sale, the director now owns 33,207 shares of the company’s stock, valued at $3,146,695.32. The trade was a 2.92 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.50% of the stock is currently owned by corporate insiders.

Lantheus Stock Down 2.5 %

Shares of LNTH opened at $79.94 on Friday. The firm has a market cap of $5.56 billion, a price-to-earnings ratio of 13.30 and a beta of 0.44. The company’s fifty day moving average is $91.43 and its 200-day moving average is $97.79. Lantheus Holdings, Inc. has a 12 month low of $56.06 and a 12 month high of $126.89.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the company. The Goldman Sachs Group initiated coverage on Lantheus in a research report on Wednesday, December 18th. They set a “buy” rating and a $143.00 price objective for the company. StockNews.com cut shares of Lantheus from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. Truist Financial reiterated a “buy” rating and issued a $120.00 price objective (down previously from $135.00) on shares of Lantheus in a research note on Friday, November 8th. Finally, JMP Securities restated a “market outperform” rating and set a $112.00 price target on shares of Lantheus in a report on Tuesday, January 14th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $131.86.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.